Osteogenesis imperfecta explained

Osteogenesis imperfecta (OI)
Pronunciation:
Field:Pediatrics, medical genetics, orthopedics
Synonyms:Brittle bone disease, Lobstein syndrome, fragilitas ossium, Vrolik disease, osteopsathyrosis idiopathica
Symptoms:Bones that break easily, blue tinge to the sclera (whites of the eye), short height, joint hypermobility, hearing loss
Onset:Birth
Onset Always:y
Duration:Long term
Causes:Genetic (autosomal dominant or de novo mutation)
Diagnosis:Based on symptoms, DNA testing
Prevention:Pre-implantation genetic diagnosis
Management:Healthy lifestyle (exercise, no smoking), metal rods through the long bones
Medication:Bisphosphonates
Prognosis:Depends on the type
Frequency:1 in 15,000–20,000 people

Osteogenesis imperfecta (; OI), colloquially known as brittle bone disease, is a group of genetic disorders that all result in bones that break easily.[1] The range of symptoms—on the skeleton as well as on the body's other organs—may be mild to severe. Symptoms found in various types of OI include whites of the eye (sclerae) that are blue instead, short stature, loose joints, hearing loss, breathing problems and problems with the teeth (dentinogenesis imperfecta).[2] Potentially life-threatening complications, all of which become more common in more severe OI, include: tearing (dissection) of the major arteries, such as the aorta;[3] pulmonary valve insufficiency secondary to distortion of the ribcage;[4] and basilar invagination.

The underlying mechanism is usually a problem with connective tissue due to a lack of, or poorly formed, type I collagen. In more than 90% of cases, OI occurs due to mutations in the COL1A1 or COL1A2 genes.[5] These mutations may be hereditary in an autosomal dominant manner but may also occur spontaneously (de novo). There are four clinically defined types: type I, the least severe; type IV, moderately severe; type III, severe and progressively deforming; and type II, perinatally lethal., 19 different genes are known to cause the 21 documented genetically defined types of OI, many of which are extremely rare and have only been documented in a few individuals. Diagnosis is often based on symptoms and may be confirmed by collagen biopsy or DNA sequencing.[6]

Although there is no cure, most cases of OI do not have a major effect on life expectancy, death during childhood from it is rare, and many adults with OI can achieve a significant degree of autonomy despite disability. Maintaining a healthy lifestyle by exercising, eating a balanced diet sufficient in vitamin D and calcium, and avoiding smoking can help prevent fractures.[7] Genetic counseling may be sought by those with OI to prevent their children from inheriting the disorder from them. Treatment may include acute care of broken bones, pain medication, physical therapy, mobility aids such as leg braces and wheelchairs, vitamin D supplementation, and, especially in childhood, rodding surgery. Rodding is an implantation of metal intramedullary rods along the long bones (such as the femur) in an attempt to strengthen them. Medical research also supports the use of medications of the bisphosphonate class, such as pamidronate, to increase bone density.[8] Bisphosphonates are especially effective in children; however, it is unclear if they either increase quality of life or decrease the rate of fracture incidence.[9]

OI affects only about one in 15,000 to 20,000 people, making it a rare genetic disease. Outcomes depend on the genetic cause of the disorder (its type). Type I (the least severe) is the most common, with other types comprising a minority of cases.[10] Moderate-to-severe OI primarily affects mobility; if rodding surgery is performed during childhood, some of those with more severe types of OI may gain the ability to walk. The condition has been described since ancient history. The Latinate term osteogenesis imperfecta was coined by Dutch anatomist Willem Vrolik in 1849; translated literally, it means "imperfect bone formation".[11]

__TOC__

Signs and symptoms

Orthopedic

The main symptom of osteogenesis imperfecta is fragile, low mineral density bones; all types of OI have some bone involvement. In moderate and especially severe OI, the long bones may be bowed, sometimes extremely so.[12] The weakness of the bones causes them to fracture easily—a study at the Endocrine Unit at the National Institute of Child Health in Karachi, Pakistan found an average of 5.8 fractures per year in untreated children.[13] Fractures typically occur much less after puberty, but begin to increase again in women after menopause and in men between the ages of 60 and 80.

Joint hypermobility is also a common sign of OI, thought to be because the affected genes are the same as those that cause some types of Ehlers–Danlos syndrome. [14] [15] [16]

Otologic

By the age of 50, about 50% of adults with OI experience significant hearing loss, much earlier as compared to the general population.[17] Hearing loss in OI may or may not be associated with visible deformities of the ossicles and inner ear.[18] Hearing loss frequently begins during the second, third, and fourth decades of life, and may be conductive, sensorineural, or a combination of both ("mixed").[19] If hearing loss does not occur by age 50, it is significantly less likely to occur in the years afterwards. Mixed hearing loss is most common among those with OI of all age groups, while conductive hearing loss is most likely to affect older people, with sensorineural hearing loss most likely to affect children.[20]

Although relatively rare, OI-related hearing loss can also begin in childhood; in a study of forty-five children aged four to sixteen, two were found to be affected, aged 11 and 15.[21] In a different 2008 study, the hearing of 41 people with OI was checked. The results showed that 88% of those over 20 years of age had some form of hearing loss, while only 38% of those under 20 did.[22]

Hearing loss is most common in type I OI; it is less common in types III and IV. Other parts of the inner ear may also be affected by OI. causing balance issues; however, only small studies have found links between vertigo and OI. OI may worsen the outcome of medical treatments which correct hearing loss.

Besides OI's association with sensorineural hearing loss, OI is associated with a number of neurological abnormalities, usually involving the central nervous system, due to deformities in the skeletal structures surrounding it. Neurological complications, especially basilar invagination, may adversely affect life expectancy. In OI, this is most often due to upwards migration of the dens, a feature of the C2 vertebra. Neurosurgery may be needed to correct severe abnormalities when they risk the patient's life or cause either great suffering or intolerable neurological deficits.[23]

Systemic

As its biological causes have been more precisely determined, it has become more widely recognized that while the primary disease process of OI happens in the bones, the most common types of OI—those caused by type I collagen gene mutations—affect virtually all of the human body's organs in some way.

Type I collagen is present throughout the circulatory and respiratory systems: from the ventricles of the heart itself, to the heart valves, to the vasculature, it is an integral part of the connective tissue of the lungs. As such, cardiovascular complications, among them aortic insufficiency, aortic aneurysm, and arterial dissections, are sometimes comorbid with OI, but not as frequently as they are comorbid with Marfan syndrome.

Respiratory illnesses are a major cause of death in OI. The most obvious source of respiratory problems in OI is pulmonary insufficiency caused by problems in the architecture of the thoracic wall. However, respiratory tract infections, such as pneumonia, are also more fatal among those with OI than the general population.[24] Those with more severe ribcage deformities were found to have worse lung restriction in a small-scale 2012 study involving 22 Italian patients with OI types III and IV, plus 26 non-affected controls.

OI—especially its severe form type III—also has effects on the gastrointestinal system. It was found to be associated with recurrent abdominal pain and chronic constipation in two studies on patients affected by OI.[25] [26] Chronic constipation is especially common, and is thought to be aggravated by an asymmetric pelvis (acetabular protrusion). Especially in childhood, OI-associated constipation may cause a feeling of fullness and associated food refusal, leading to malnutrition.

Classification

There are two typing systems for OI in modern use. The first, created by David Sillence in 1979, classifies patients into four types, or syndromes, according to their clinical presentation, without taking into account the genetic cause of their disease.[27] [28] The second system expands on the Sillence model, but assigns new numbered types genetically as they are found. Therefore, people with OI can be described as having both a clinical type and a genetic type, which may or may not be equivalent.

Type I is the most common, and 90% of cases result from mutations to either COL1A1 or COL1A2. Symptoms vary widely between types, as well as vary from person to person, even in the same family.[29]

As of 2021, 21 types of OI have been defined:[30] [31]

Sillence's four types
Type Description GeneMode of inheritanceIncidenceDefined[32] - mild Null COL1A1 allele autosomal dominant, 34% de novo[33] 1 in 30,000[34] 1979 - lethal in the perinatal period COL1A1, COL1A2 autosomal dominant, ≈100% de novo1 in 40,000[35] to 1 in 100,000 - severe, progressive and deforming COL1A1, COL1A2 autosomal dominant, 85% de novo1 in 60,000 - variable and deforming, but usually with normal scleraeCOL1A1, COL1A2 autosomal dominant, 50% de novo1 in 30,000
Genetically defined types
Type Gene Mode of inheritance[36] Defined
IFITM5autosomal dominant[37] [38] 2000[39] - SERPINF1autosomal recessive2002 - CRTAPautosomal recessive2006 - LEPRE1autosomal recessive2007 - PPIBautosomal recessive2009 - SERPINH1autosomal recessive2010 - FKBP10autosomal recessive2010 - SP7autosomal recessive2010 - BMP1autosomal recessive2012 - TMEM38Bautosomal recessive2012 - WNT1autosomal recessive2013 - CREB3L1autosomal recessive2013 - SPARCautosomal recessive2015 - TENT5Aautosomal recessive2018 - MBTPS2X-linked recessive2016 - MESDautosomal recessive2019
KDELR2autosomal recessive2020

Sillence types

Sillence's four types have both a clinical and a genetic meaning; the descriptions below are clinical and can be applied to several genetic types of OI. When used to refer to a genetic as well as a clinical type, it indicates that the clinical symptoms are indeed caused by mutations in the COL1A1 or COL1A2 genes which are inherited in an autosomal dominant fashion.

Type

Collagen is of normal quality but is produced in insufficient quantities. Bones fracture more easily than in the general public, but not as easily as more severe types of OI; there might be scoliosis, albeit mild compared to OI types III and IV, with a lower Cobb angle; the joints may be loose; blue sclerae may be apparent; hearing loss is likely to occur; and there might be a slight decrease in height. Because cases exist missing one or more of these symptoms, OI type I in some cases goes undetected into adulthood.

Some further split type I into types I–A and I–B, defined as being distinguished by the absence (I–A) or presence (I–B) of dentinogenesis imperfecta (opalescent teeth).[40] People with type I generally have a normal lifespan.[41]

Type

Collagen is fatally defective at its C-terminus. Most cases result in death shortly after birth, or within the first year of life, due to respiratory failure. Another common cause of death is intracranial bleeds from skull fractures present at, or sustained during or shortly after, birth. In many cases, the newborn already has multiple broken bones at the time of birth. Type II infants also exhibit severe respiratory problems, and have severely deformed bones. Sixty percent of infants die less than 24 hours after being born, and survival after the first year is extremely unlikely and normally requires mechanical ventilation.[42] In the rare cases of infants who survive their first year of life, severe developmental and motor delays are seen; neither of two infants studied in 2019, both aged around two years, had achieved head control, and both required a ventilator to breathe.[43]

Type II is also known as the "lethal perinatal" form of OI,[44] and is not compatible with survival into adulthood. Due to similarly severely deformed bones, sometimes infants with severe type III are wrongly initially classified as type II; once long-term survival is shown, they are considered as having type III instead.[45]

Type

Collagen quantity is sufficient, but is not of a high enough quality. Clinical differentiation between types III and IV is not always simple, and is further confounded by the fact that an untreated adult with type IV may have worse symptoms than a treated adult with type III;[46] features only found in type III are its progressively deforming nature and the presence of a face with a "triangular" appearance.[47] Another differentiating factor between type III and IV is blue sclerae; in type III, infants commonly have blue sclerae that gradually turn white with age, but blue sclerae are not commonly seen in type IV,[48] although they are seen in 10% of cases.[49]

OI type III causes osteopenic bones that fracture very easily, sometimes even in utero, often leading to hundreds of fractures during a lifetime; early scoliosis that progresses until puberty; dwarfism (a final adult height frequently less than 4feet); loose joints; and possible respiratory problems due to low rib cage volume causing low lung volumes.

Due to the severity of the issues with the bones, neurological and seizure disorders are more likely to develop in type III. Basilar invagination, which puts pressure on the brainstem, may cause or contribute to early death; surgical treatment of it is more complex in OI cases.

Type

Collagen quantity is sufficient, but is not of a high enough quality. Type IV is for cases of variable severity, which do not fit into either types III or I.[50] While one of Sillence's required characteristics for type IV was having normal sclerae, modern classification allows even those with blue sclerae to fit the criteria for type IV if they meet the other clinical requirements of the type.

In type IV, bone deformity can be mild to severe, bones fracture easily (especially before puberty), dwarfism is common, vertebral collapse and scoliosis are evident, and hearing loss is possible, although uncommon. Type IV OI is mostly defined in contrast to type III and type I, being the clinical classification for patients somewhere in the middle ground between the two. As such, type IV OI is often termed "variable" OI, with the severity of even those in the same family (so, with the same genetic mutation) differing.

Prepubertal bone fracture rates are another way of clinically assessing type IV OI—those with it tend to have fracture rates of ≈1 per year, compared to ≈3 per year for severe OI (type III).

As in type I, some further split type IV into types IV–A and IV–B, defined again by the absence (IV–A) or presence (IV–B) of dentinogenesis imperfecta.

Genetically defined types (types –)

As of 2020, fifteen types of OI are defined genetically:

Given the rapid rate of type discovery, it is extremely likely that there are other genes associated with OI that have yet to be reported.[70]

Genetics

Osteogenesis imperfecta is a group of genetic disorders, all of which cause bone fragility. OI has high genetic heterogeneity, that is, many different genetic mutations lead to the same or similar sets of observable symptoms (phenotypes).[71]

The main causes for developing the disorder are a result of mutations in the COL1A1 and/or COL1A2 genes which are jointly responsible for the production of collagen type I.[72] Approximately 90% of people with OI are heterozygous for mutations in either the COL1A1 or COL1A2 genes.[73] There are several biological factors that are results of the dominant form of OI. These factors include: intracellular stress; abnormal tissue mineralization; abnormal cell to cell interactions; abnormal cell-matrix interactions; a compromised cell matrix structure; and, abnormal interaction between non-collagenous proteins and collagen.[74]

Previous research led to the belief that OI was an autosomal dominant disorder with few other variations in genomes.[75] However, with the lowering of the cost of DNA sequencing in the wake of 2003's Human Genome Project, autosomal recessive forms of the disorder have been identified.[76] Recessive forms of OI relate heavily to defects in the collagen chaperones responsible for production of procollagen and the assembly of the related proteins.[77] Examples of collagen chaperones that are defective in patients with recessive forms of OI include chaperone HSP47 (Cole-Carpenter syndrome) and FKBP65.[78] Mutations in these chaperones result in an improper folding pattern in the collagen 1 proteins which causes the recessive form of the disorder. There are three significant types of OI that are a result of mutations in the collagen prolyl 3-hydroxylation complex (components CRTAP, P3H1, and CyPB). These components are responsible for the modification of collagen α1(l)Pro986. Mutations in other genes such as SP7, SERPINF1, TMEM38B and BMP1 can also lead to irregularly formed proteins and enzymes that result in other recessive types of osteogenesis imperfecta.

Defects in the proteins pigment epithelium-derived factor (PEDF) and bone-restricted interferon-induced transmembrane protein (BRIL) are the causes of type V and VI osteogenesis imperfecta.[79] Defects in these proteins lead to defective bone mineralization which causes the characteristic brittle bones of osteogenesis imperfecta. A single point mutation in the 5′ untranslated region (5′ UTR) of the IFITM5 gene, which encodes BRIL, is linked directly to OI type V.[80]

In the rare case of type XIX, first discovered in 2016, OI is inherited as an X-linked genetic disorder, with its detrimental effects resulting ultimately from a mutation in the gene MBTPS2.[81] Genetic research is ongoing, and it is uncertain when all the genetic causes of OI will be identified, as the number of genes that need to be tested to rule out the disorder continue to increase.

In a study of 37 families, a 1.3% chance was found that OI recurs in multiple siblings born to two unaffected parents—this is a much higher rate than would be expected if all such recurrences were de novo.[82] The cause is genetic mosaicism; that is, some of, or most of, the germ cells of one parent have a dominant form of OI, but not enough of their somatic cells do to cause symptoms or obvious disability in the parent—the parent's different cells have two (or more) sets of slightly different DNA. It has been clinically observed that ≈5–10% of cases of OI types II and III are attributable to genetic mosaicism.

Pathophysiology

People with OI are either born with defective connective tissue, born without the ability to make it in sufficient quantities, or, in the rarest genetic types, born with deficiencies in other aspects of bone formation such as chaperone proteins, the Wnt signaling pathway, the BRIL protein, et cetera. In type I the collagen's structure itself is normal, it is just its quantity that is low. Types II, III and IV are usually, but not always, related to a deficiency of type I collagen.[83] One possible deficiency arises from an amino acid substitution of glycine to a bulkier amino acid, such as alanine, in the collagen protein's triple helix structure. The larger amino acid side-chains lead to steric effects that creates a bulge in the collagen complex, which in turn influences both the molecular nanomechanics and the interaction between molecules, which are both compromised.[84] [85] Depending on both the location of the substitution and the amino acid being used instead, different effects are seen which account for the type diversity in OI despite the same two collagen genes being responsible for most cases.[86] Replacements of glycine with serine or cysteine are seen less often in fatal type II OI, while replacements with valine, aspartic acid, glutamic acid, or arginine are seen more often.

At a larger scale, the relationship between the collagen fibrils and hydroxyapatite crystals to form bone is altered, causing brittleness. Bone fractures occur because the stress state within collagen fibrils is altered at the locations of mutations, where locally larger shear forces lead to rapid failure of fibrils even at moderate loads because the homogeneous stress state normally found in healthy collagen fibrils is lost. OI is therefore a multi-scale phenomenon, where defects at the smallest levels of tissues (genetic, nano, micro) domino to affect the macro level of tissues.

Diagnosis

Diagnosis is typically based on medical imaging, including plain X-rays, and symptoms. In severe OI, signs on medical imaging include abnormalities in all extremities and in the spine.[87] As X-rays are often insensitive to the comparatively smaller bone density loss associated with type I OI, DEXA scans may be needed.

An OI diagnosis can be confirmed through DNA or collagen protein analysis, but in many cases, the occurrence of bone fractures with little trauma and the presence of other clinical features such as blue sclerae are sufficient for a diagnosis. A skin biopsy can be performed to determine the structure and quantity of type I collagen. While DNA testing can confirm the diagnosis, it cannot absolutely exclude it because not all mutations causing OI are yet known and/or tested for. OI type II is often diagnosed by ultrasound during pregnancy, where already multiple fractures and other characteristic features may be visible. Relative to control, OI cortical bone shows increased porosity, canal diameter, and connectivity in micro-computed tomography.[88] OI can also be detected before birth by using an in vitro genetic testing technique such as amniocentresis.[89]

Genetic testing

In order to determine whether osteogenesis imperfecta is present, genetic sequencing of the most common problematic genes, COL1A1, COL1A2, and IFITM5, may be done;[90] if no mutation is found yet OI is still suspected, the other 10+ genes known to cause OI may be tested. Duplication and deletion testing is also suggested to parents who suspect their child has OI. The presence of frameshift mutations caused by duplications and deletions is generally the cause of increased severity of disease.

Differential diagnosis

An important differential diagnosis of OI is child abuse, as both may present to a clinician with multiple fractures in various stages of healing. Differentiating them can be difficult, especially when no other characteristic features of OI are present. This can become an issue in court; in the United States, several child abuse cases were resolved with a finding that osteogenesis imperfecta was the true cause of a child's fractures, leading to lawsuits seeking redress such as Alice Velasquez, et al. v. United States.[91]

Other differential diagnoses include rickets and osteomalacia, both caused by malnutrition, as well as rare skeletal syndromes such as Bruck syndrome, hypophosphatasia, geroderma osteodysplasticum, and Ehlers–Danlos syndrome. Various forms of osteoporosis, such as iatrogenic osteoporosis, idiopathic juvenile osteoporosis, disuse osteoporosis and exercise-related osteoporosis should also be considered as explanations when OI is suspected.

Treatment

There is no cure for osteogenesis imperfecta.[6] Maintaining a healthy lifestyle by exercising and avoiding smoking can help prevent fractures.[92] Treatment may include care of broken bones, pain medication, physical therapy, mobility aids such as braces or wheelchairs, and surgery.

Judging the success or failure of treatment can be difficult in OI patients, as decreased bone fracture rates may just be coincidental. While these rates are often used in medical studies to judge treatment efficacy, a Norwegian study of fifteen people with OI emphasized that they feel doctors should consider the whole patient and not just fracture rates.[93]

Acute bone fracture care

Bone fractures are treated in individuals with osteogenesis imperfecta in much the same way as they are treated in the general population—OI bone heals at the same rate as non-OI bone. A greater emphasis is placed on using lightweight materials to immobilize the fracture, as in moderate or severe types of OI, using heavy casts, such as hip spica casts, can cause fractures at the bones at the boundaries of the cast, as well as generalized osteopenia. The lightweight cast or splint is then replaced with a removable orthosis after a few weeks and once evidence of union is seen on X-ray. In order to prevent a nonunion or malunion, all fractures should be immobilized, even if the fracture seems trivial (microfracture), as people with OI are at greater risk of nonunion.

Bone infections secondary to fractures are treated as and when they occur with the appropriate antibiotics and antiseptics, as in the general population.

Medications

Bisphosphonates

In 1998, an initial observational trial demonstrated the effectiveness of intravenous pamidronate, a bisphosphonate which had previously been used in adults to treat osteoporosis. In severe OI, this trial showed that pamidronate reduced bone pain, prevented new vertebral fractures, reshaped previously fractured vertebral bodies, and reduced the number of long-bone fractures.[94]

Although oral bisphosphonates are more convenient and cheaper, they are not absorbed as well, and intravenous bisphosphonates are generally more effective, although this is under study. Some studies have found oral and intravenous bisphosphonates, such as oral alendronate and intravenous pamidronate, equivalent.[95] In a 2013 double-blind trial of children with mild OI, oral risedronate increased bone mineral densities, and reduced nonvertebral fractures. However, it did not decrease new vertebral fractures.[96] [97] A Cochrane review in 2016 concluded that though bisphosphonates seem to improve bone mineral density, it is uncertain whether this leads either to a reduction in bone fractures or improvement in the quality of life of individuals with osteogenesis imperfecta.[9] Even in trials with as many as 125 children, no causal link has been found between bisphosphonates and decreased fracture rates; placebo controlled trials were also unable to prove that they brought about increased strength, motor control or lower pain levels.

Bisphosphonates are not as effective at increasing the bone mineral density of adults.[98]

Nutritional supplements

OI is a genetic disorder and is not caused by insufficient intake of any vitamin or mineral; supplementation cannot cure OI. Nevertheless, people with OI tend to be severely deficient in vitamin D at much higher rates than the general population, and the cause of this is not well understood.[99] [100] [101] The severity of the deficiency and the likelihood of its occurrence is thought to be related to severity of OI. Vitamin D supplementation may be recommended, at least until levels of 25(OH)D3 in a patient's blood return to normal. Vitamin D deficiency is also a concern as it may decrease the benefit of bisphosphanates.

Surgery

A surgery of any type inherently carries more risks when done on a patient who has (especially moderate to severe) OI. Skeletal deformities and dentinogenesis imperfecta may hinder access to the airway. Use of, and weaning off of, mechanical ventilation is also more challenging to carry out on patients with OI. During the procedure itself or the healing process, defective OI collagen may lead to bleeding diatheses.

The safety of anesthesia is also of more concern among patients with OI, with anesthetic complications 5.6x more likely to occur when the patient has OI type III.[102] A unique concern of anesthesia in OI is perioperative fracture—fractures sustained due to patient transfer and airway access techniques that, while routine when a patient's bones are strong, may cause injury with brittle OI bones.[103] As an example, due to a 1972 report of a humerus fracture from a sphygmomanometer cuff sustained in an OI patient during surgery, blood pressure monitoring protocols are often modified for patients with OI, with neonatal size cuffs and machine settings being used even in adults; further, the least deformed of the patient's limbs is preferred to receive the cuff.

Rodding

Metal rods can be surgically inserted in the long bones to improve strength, a procedure developed by Harold A. Sofield when he was Chief of Staff at Chicago's Shriners Hospitals for Children, a hospital that offers orthopedic care and surgery to children regardless of their family's ability to pay.[104] Large numbers of children with OI came to Shriners, and Sofield experimented with various methods to strengthen their bones.[105] In 1959, with Edward A., Sofield wrote a seminal article describing a three-part surgery that seemed radical at the time: precisely breaking the bones ("fragmentation"), putting the resulting bone fragments in a straight line ("realignment"), then placing metal rods into the intramedullary canals of the long bones to stabilize and strengthen them ("rod fixation").[106] His treatment proved useful for increasing the mobility of people with OI, and it has been adopted throughout the world—it became standard surgical treatment for severe OI by 1979, in which year David Sillence found that ≈ of the patients he surveyed with OI type III had undergone at least one rodding surgery.

Rodding surgery is often done with the hope that it will offer a path to ambulation, walking, to patients with moderate or severe OI. A 2020 review in The Journal of Bone and Joint Surgery (JB&JS) found it remains broadly popular: ≈ of people with OI types III and IV (severe OI) have undergone some form of rodding surgery in their lives, at a mean age of and years respectively;[107] one possible explanation for a tendency towards earlier intervention in type III is that one half of affected children could not walk at all without the surgery, as their limbs were more bowed, so surgery was sought sooner.

In those with type III OI who had undergone rodding surgery, 79.5% had the femurs and tibias of both legs rodded. The most common form of rods used are intramedullary (IM) rods, some of which, such as the Fassier–Duval IM rod, are telescoping, meaning that they are designed to grow as the child grows, in an attempt to avoid the necessity of revision surgeries.[108] Telescoping IM rods are widely used,[109] and the common Fassier–Duval IM rod is designed to be used to rod the femur, tibia, and humerus.[110] The surgery involves breaking the long bones in between one and three (or more) places, then fixing the rod alongside the bone to keep it straight.

While telescoping IM rods are intended to grow along with both the femur and tibia in developing children; surgeons have a preference to use non-telescoping IM rods, such as Rush rods, in the tibia, which grows less comparatively—the JB&JS review found that while 69.7% of femurs were treated with telescoping IM rods, only 36.9% of tibiae were.

While the review in the JB&JS was able to correlate receiving rodding surgery with greater mobility across all types of OI, in patients with type IV, the surgery did not decrease the incidence of broken bones as compared to non-rodded patients—while type IV patients with rodded tibiae experienced 0.93 tibia fractures per year, patients with natural tibiae experienced only 0.81. However, in patients with type III, rodding surgery decreased the average number of tibia fractures per year from 0.84 to 0.57.

Spinal

Spinal fusion can be performed either as a preventative measure or to correct existing scoliosis, although the inherent fragility of OI bone makes this operation more complex in OI patients than it does with patients who have adolescent idiopathic scoliosis, but normal bone density.[111] Despite the risks, however, three Nemours–duPont orthopedic surgeons who specialize in surgical intervention for osteogenesis imperfecta recommend operating if the curve is greater than 50° after a child is past peak height velocity, as the spine's curve can continue to worsen even into adulthood.[112]

Due to the risk involved, the same surgeons recommend that surgery for basilar impressions and basilar invaginations should only be carried out if the pressure being exerted on the spinal cord and brain stem is causing actual neurological symptoms. Once basilar invagination has become symptomatic, only surgery can halt or reverse the progression of neurological deficits.

Physical therapy

Physical therapy is generally recommended, however individualized protocols are required due to the variability of OI. Physical therapy is used to strengthen muscles, improve motility, improve flexibility, and help with weight maintenance, although it must be done in a gentle manner to minimize the risk of bone fracture. In people with OI, exercise often involves water aerobics, light resistance exercises, and walking, if the patient is able. However, even in patients with mild OI, contact sports, as well as activities likely to put unnecessary stress on the joints, such as jumping, are contraindicated due to the risks they pose.

Individuals with more limited mobility are encouraged to change positions regularly throughout the day; people who sit in a wheelchair most or all of the day are recommended to get out of it every two hours, as a form of exercise, to decrease stiffness, and to prevent pressure ulcers.

Individuals with moderate to severe OI, who require assistive mobility devices and adapted vehicles, face significant barriers to access wheelchair-accessible pools or gyms—they either may not have any in their area, nor the means to get there. Obesity may be more likely to present among those with severe OI, (especially after the age of 20,) and can, in some, cause further declines in mobility.[113]

Tilt table whole body vibration may also be done to increase the mobility of long-term immobilized (bedridden) patients with OI; in at least two cases it helped bedridden children to be able to sit upright.[114]

Teeth

See also: Dentinogenesis imperfecta. More than 1 in 2 people with OI also have dentinogenesis imperfecta (DI)—a congenital abnormality in the formation of dentin, one of the four major components of the human tooth.[115] Dental treatment may pose as a challenge as a result of the various deformities, skeletal and dental, due to OI. Children with OI should go for a dental check-up as soon as their teeth erupt; this may minimize tooth structure loss as a result of abnormal dentine, and they should be monitored regularly to preserve their teeth and oral health.

Many people with OI are treated with bisphosphonates, and there are several possible related complications with dental procedures, for example, medication-related osteonecrosis of the jaw (MRONJ). However, no report of bisphosphonate-related MRONJ in either a child or adult with OI was found in a 2016 Cochrane review of the safety and efficacy of bisphosphonates for OI.

In development

Monoclonal antibodies

Monoclonal antibodies have long been considered for OI, but as of 2021, such therapy has not been approved for OI, neither in the European Union nor in the United States. Thus, it is unclear whether they are safe or effective. Among the monoclonal antibodies that have been studied are romosozumab (targets sclerostin, by Amgen), fresolimumab (TGF-β, Sanofi), blosozumab (sclerostin, Lilly), and setrusumab (sclerostin, begun by Novartis).[116]

Setrusumab, formerly known as BPS-804, is a monoclonal antibody that targets sclerostin, and has been studied in OI specifically more than any of the others. In the body, sclerostin binds to the LRP5 and LRP6 receptors, resulting in inhibition of the Wnt signaling pathway. This decreases bone formation, and is not a problem when a person has healthy bones.[117] It is thought, though, that decreasing the concentration of sclerostin in the body may lead to the formation of more bone, and that is the premise as to why monoclonal antibodies that reduce the concentrations of naturally occurring sclerostin may help strengthen OI bone.[118] While setrusumab was first developed at the pharmaceutical company Novartis, Novartis sold its rights to patent the drug to Mereo Biopharma in 2015, who has continued its development in conjunction with Ultragenyx.[119] In 2019, Mereo announced that it had concluded collecting data for its phase II-B trial of setrusumab; the study was completed on 12 November 2020.[120] Despite the trial data failing to show improvements in bone density on QCT scans, its primary goal, there were improvements on DXA scans.[121] In a September 2020 press release, Mereo said it was seeking to do a phase III trial in 2021, and had received a Rare Pediatric Disease (RPD) designation from the US Food and Drug Administration (FDA).[122]

Romosozumab, which also is a monoclonal antibody targeting sclerostin, is an approved drug in the US and EU for the treatment of osteoporosis. The pharmaceutical industry analyst Evercore has remarked that "it could wipe out setrusumab's economics", as romosozumab is priced more cheaply than a drug for a rare disease would be, claiming that it will be "vital" to Ultragenyx's profit margins to prove its setrusumab is more efficacious than romosozumab for OI. A clinical trial evaluating romosozumab's efficacy in OI began in September 2020 and as of September 2021 is ongoing.[123] Ultragenyx predicts that its phase 2/3 trials for setrusumab will be completed in 2026.[124] [125]

Prevention

See also: Introduction to genetics and bioethics. As a genetic disorder, the mainstay of twenty-first century prevention of osteogenesis imperfecta is based on preventing affected individuals from being born in the first place. Genetic counseling can help patients and their families determine what types of screening, if any, are right for their situation. Patients can consider preimplantation genetic diagnosis after in vitro fertilization to select fertilized embryos which are not affected. Common mutations which cause OI may be caught by exome sequencing and whole genome sequencing. If a pregnancy is already in progress, the procedure of amniocentesis may be undergone to see if the fetus is affected. If affected, it is up to the family to consider whether or not they want to terminate the pregnancy and try again—raising questions of medical ethics and a woman's right to choose.[126] [127]

Without intervention, patients with the most common mutations causing osteogenesis imperfecta have a 50% chance per gestation of passing on the disorder, as these mutations are inherited in an autosomal dominant pattern of Mendelian inheritance. Those with the rare autosomal recessive forms of OI have a 25% chance of passing on the disorder. Genetic testing of the affected members of the family can be used to determine which inheritance pattern applies.

As OI type I may be difficult to detect in a newborn child, the cord blood of the child can be tested to determine if it has been passed on if the family has already rejected the more invasive genetic screening methods. In more severe cases, the diagnosis may be able to be done via ultrasound, especially if OI is already a possibility. An ethical concern with prenatal screening for OI often arises when parents inquire as to how severely affected their child will be—such questions are as yet difficult to answer conclusively.

If a non-affected person has already had a child with OI, there is a greater likelihood (although still quite remote), that their future children will have OI due to genetic mosaicism.

The disability rights critique of prenatal screening for OI, held by some bioethicists and some affected individuals, negatively compares it to eugenics, with even those not opposed to abortion opposing selective abortions on the ethical ground that their existence betrays the belief that the lives of those with OI are "less worth living [and] less valuable".

Prognosis

The prognosis of osteogenesis imperfecta depends entirely on its type (see).

Life expectancy

In the mild form of the disorder, type I, the life expectancy of patients is near that of the general population. In type II, however, patients only very rarely live past the age of two, and typically die in their first weeks of life. Assessment of the life expectancy of patients with types III and IV is more complicated, as lifestyle choices can cause fatally traumatic injuries that would not have otherwise occurred, or not been fatal in the general population. Life expectancy in type IV OI is thought to be close to normal, but in type III it is lower than in the general population.

A 2016 study of data in Denmark's found that across all types of OI, all-cause mortality was three times higher, leading to a loss of around seven years in females and nine years in males.[128] A 1996 study published in the British Medical Journal found that mortality in type III OI is significantly higher, with many patients dying in their 20's, 30's, and 40's; patients who survive to the age of 10 were further found to have longer life expectancy than newborns.[129]

Mobility

People with mild (type I) OI as adults need few pieces of adaptive equipment, although in infancy they reach motor milestones at a significant delay compared to the general population.

With adaptive equipment such as crutches, motorized wheelchairs, splints, reach extenders, and/or modifications to the home, many individuals with moderate to severe OI can achieve or maintain a significant degree of independence.[130] With treatment and physical therapy, the maximum levels of mobility are expected to be unassisted community walking for type I, household or exercise walking for type III, and household or community walking for type IV; due to the variability of OI between individuals, mobility achieved varies and may be below this expected maximum.

Epidemiology

In the United States, the incidence of osteogenesis imperfecta is estimated to be one per 20,000 live births.[131] An estimated 20,000 to 50,000 people are affected by OI in the United States.[132]

The most common types are I, II, III, and IV, while the rest are very rare.[133] Type I is the most common and has been reported to be around three times more common than type II. The prevalence of types III and IV is less certain. In a 1989 study in Denmark, type I was found to comprise 71% of cases and type II 12% of cases, with other types comprising the other 17%. In a 2015 study in Sweden, type I was nearly six times more common than type III and nearly four times more common than type IV.

Most people with OI receive it from a parent, but in many cases, it is a brand new (de novo or "sporadic") mutation in a family. Among a study of patients with survivable types of OI, OI type III is most often de novo (85%), followed by type IV (50%) and type I (34%).

Some populations can have a higher incidence of OI than would be otherwise expected if they have a larger than average number of carriers of the recessive forms of the disease.[134]

History

The condition, or types of it, has had various other names over the years and in different nations; "osteogenesis imperfecta" has, however, been the most widely accepted name for the condition since the late 20th century. Among some of the most common alternatives are "fragilitas ossium";[135] "Ekman–Lobstein syndrome", and "Vrolik syndrome", both eponyms; and, the colloquialism, "brittle bone disease".

Earliest recorded cases

OI has been identified in an ancient Egyptian infant mummified in around 1000 BC, originally dismissed by archaeologists as containing the remains of a monkey.[136] [137] The Norse king Ivar the Boneless, who lived,[138] is speculated to have had OI as well.[139]

Nicolas de Malebranche is oft credited as being the first person to describe the physical characteristics of OI in his 1688 book, in which he describes a man who has had his "bones broken in the places a murderer's would be" all his life. His confident description of the pathology of the disorder, however, which creates what he termed «French: enfants monstrueux» ("monstrous children"), is scientifically void—he wrote that it was due to the mother's antepartum viewership of a public execution by breaking wheel.[140] [141]

The earliest modern scientific studies of OI began in 1788 by Olof Jakob Ekman, who described the condition, which he termed "osteomalacia congenital", in his doctoral thesis and mentioned cases of it going back to 1678, all in the same family, through three generations.[142] Ekman's description of the condition mentioned dwarfism, bone fragility, and bowing of the long bones.[143] In 1831, Edmund Axmann gave a detailed description of it in himself and his two brothers, being the first to mention blue sclerae as a characteristic sign of OI. Jean Lobstein first described the mild form of the condition, today known as type I, in 1833, calling it "osteopsathyrosis idiopathica".[144]

It was not until 1912 that hearing loss was positively recognized as a symptom of OI, first mentioned in a brief paper by the English physician Charles Allen Adair-Dighton.[145]

Of the term

Willem Vrolik, a Dutch anatomist who was also curator of the "Museum Vrolikianum", which made him privy to many specimens of bodies having birth defects, coined the term "osteogenesis imperfecta"[140] in his bilingual Latin and Dutch language book on teratology, Illustrations of Human and Mammalian Embryogenesis, first published in 1849.[146]

Included is a description of the remains of an infant who had what is now known as perinatally fatal OI type II (as verified in a 1998 re-examination of the remains by Baljet et al.).[147] The remains were first given to Vrolik's father, who could not make sense of them. Vrolik described poorly mineralized bones, bowed long bones, and fractures in various states of healing.[148] Vrolik correctly determined that what he termed OI in the infant was not caused by secondary rickets, but a congenital abnormality causing primary osteopenia; he theorized this was due to a lack of "intrinsic generative energy".

Of its classification

Classification of OI has also evolved as scientific understanding of it has improved. Before the advent of modern genetic testing, OI was classified in two broad groups: osteogenesis imperfecta congenita, and osteogenesis imperfecta tarda, a division first proposed by the German physician E. Looser in 1906.[149] Congenita was used to describe the modern clinical types II, III, and some cases of IV, where upon birth the condition was obvious, either due to bowing of the limbs or due to fractures sustained in utero. Tarda was used to classify the modern OI type I and some cases of type IV, where the inherent fragility of the bones did not become clear until long after birth. The idea that these "late" and "prenatal" forms were manifestations of the same disorder was first proposed in 1897 by Martin Benno Schmidt; by the 1950s this fact was well accepted.

The modern system of four types (I, II, III, IV), meanwhile, were introduced in a paper by David Sillence, Alison Senn, and David Danks in the Journal of Medical Genetics in 1979,[150] and have since become standard terms among doctors, patients, and researchers. The modern genetic types, (those with numbers greater than IV,) have come into use as more and more recessively inherited forms of OI have been discovered since the discovery of the first one by Roy Morello et al. in 2006. In 2010, the International Nomenclature Group for Constitutional Disorders of the Skeleton (INCDS) "freed" the Sillence types from molecular reference, acquiescing to their new clinical-first role in the wake of what was to them a "surprising" increase in the number of genetic causes of OI.[151]

Writing for the Annual Review of Genetics in 2012, Drs. Peter Byers and Shawna M. Pyott lamented how the expansion of the number of types to include genetic types has created a system that "grew like Topsy". They suggest that it may indeed be impossible to create a system which is useful for clinicians and which accurately describes the genetic cause of a person's OI, with attempts always prioritizing one use at the expense of the other.

Society and culture

See also: List of people with osteogenesis imperfecta. Much medical research has been done into the causes of osteogenesis imperfecta, benefiting not only those with OI but medicine more broadly; in the ten years between 2006 and 2016, the many discoveries of non-collagen related recessive gene mutations, which still led in those who have them to the clinical signs of OI, led to numerous breakthroughs in medical understanding of the process of healthy bone development.

Other animals

In dogs, OI is an autosomal recessive condition, meaning that dogs with two copies of the allele will be affected.[152] Many breed organizations and veterinarians offer OI tests to tell if a dog is a carrier of OI.[153] To prevent OI, dogs who are heterozygous for OI should only be bred to non-carriers.

Naturally occurring mutations causing OI have been found in Golden Retrievers, Dachshunds, and Beagles. OI has also been identified in zebrafish and mice.[154]

Although dogs, mice, fish, and humans are not genetically identical, some of these animal models have been officially recognized to represent the varying types of OI in humans. For example, homozygous oim/oim mice experience spontaneous bone fractures, small body size, and kyphosis, making them a model of OI type III. Meanwhile, heterozygous oim/+ mice appear normal but have bones which are quite a bit weaker than wild mice, making them a model for OI type I.[155] As in human OI, the location on the gene which is mutated affects the severity of resulting disease—the G859C Col1a1 mouse is a model for OI type II as affected mice all die in the perinatal period.

Animal testing on identified animal models may lead to human therapies for OI.

External links

Notes and References

  1. Web site: 2020-08-18. Osteogenesis imperfecta. live. https://web.archive.org/web/20210829154516/https://medlineplus.gov/genetics/condition/osteogenesis-imperfecta/. 29 August 2021. 2021-08-15. Genetics Home Reference. U.S. National Library of Medicine, National Institutes of Health.
  2. Book: Principles of bone biology. Rowe DW. Elsevier. 2008. 978-0-12-373884-4. 3rd. Amsterdam. 1511–1531. Osteogenesis imperfecta. 267135745. Dentinogenesis imperfecta (DI) is most frequent in OI types III and IV, and overall, affects about 15% of OI patients among the different phenotypes.. 15 August 2021. 20 September 2021. https://web.archive.org/web/20210920212533/https://www.worldcat.org/title/principles-of-bone-biology/oclc/267135745. live.
  3. McNeeley MF, Dontchos BN, Laflamme MA, Hubka M, Sadro CT . Aortic dissection in osteogenesis imperfecta: case report and review of the literature . Emergency Radiology . 19 . 6 . 553–556 . December 2012 . 22527359 . 10.1007/s10140-012-1044-1 . 11109481 .
  4. LoMauro A, Pochintesta S, Romei M, D'Angelo MG, Pedotti A, Turconi AC, Aliverti A . Rib cage deformities alter respiratory muscle action and chest wall function in patients with severe osteogenesis imperfecta . PLOS ONE . 7 . 4 . e35965 . 2012-04-27 . 22558284 . 3338769 . 10.1371/journal.pone.0035965 . free . 2012PLoSO...735965L .
  5. Book: The Bone and Mineral Manual: A Practical Guide. Shapiro JR, Sponseller PD. 2005-08-23. Elsevier Inc.. 978-0-08-047074-0. Kleerekoper M, Siris ES, McClung M. 45. en. 10—Osteogenesis Imperfecta. 17 September 2021. 20 September 2021. https://web.archive.org/web/20210920212532/https://books.google.com/books?id=grNNko25htwC&newbks=0. live.
  6. Web site: Lee B, Krakow D. July 2019. Osteogenesis Imperfecta Overview. live. https://web.archive.org/web/20210509104555/https://www.bones.nih.gov/health-info/bone/osteogenesis-imperfecta/overview. 2021-05-09. 2021-08-21. National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health.
  7. Web site: November 2018. What People With Osteogenesis Imperfecta Need To Know About Osteoporosis. live. 2021-09-18. Osteoporosis and Related Bone Diseases National Resource Center. National Institutes of Health. 18 March 2021. https://web.archive.org/web/20210318041959/https://bones.nih.gov/health-info/bone/osteoporosis/conditions-behaviors/osteoporosis-oi.
  8. Harrington J, Sochett E, Howard A . Update on the evaluation and treatment of osteogenesis imperfecta . Pediatric Clinics of North America . 61 . 6 . 1243–1257 . December 2014 . 25439022 . 10.1016/j.pcl.2014.08.010 .
  9. Dwan K, Phillipi CA, Steiner RD, Basel D . Bisphosphonate therapy for osteogenesis imperfecta . The Cochrane Database of Systematic Reviews . 2016 . CD005088 . October 2016 . 10 . 27760454 . 6611487 . 10.1002/14651858.CD005088.pub4 .
  10. Lindahl K, Åström E, Rubin CJ, Grigelioniene G, Malmgren B, Ljunggren Ö, Kindmark A . Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta . European Journal of Human Genetics . 23 . 8 . 1042–1050 . August 2015 . 25944380 . 4795106 . 10.1038/ejhg.2015.81 .
  11. Book: Kelly EB . Encyclopedia of Human Genetics and Disease. 2012. ABC-CLIO. 9780313387135. 613. live. https://web.archive.org/web/20171105195021/https://books.google.com/books?id=gqMYt17klVIC&pg=PA613. 2017-11-05.
  12. Johnson MT, Morrison S, Heeger S, Mooney S, Byers PH, Robin NH . A variant of osteogenesis imperfecta type IV with resolving kyphomelia is caused by a novel COL1A2 mutation . Journal of Medical Genetics . 39 . 2 . 128–132 . February 2002 . 11836364 . 1735034 . 10.1136/jmg.39.2.128 .
  13. Atta I, Iqbal F, Lone SW, et al. . 2014 . Effect of Intravenous Pamidronate Treatment in Children with Osteogenesis Imperfecta . live . Journal of the College of Physicians and Surgeons Pakistan . Karachi . 24 . 9 . 653–657 . 25233970 . https://web.archive.org/web/20210817061150/https://www.jcpsp.pk/archive/2014/Sep2014/11.pdf . 17 August 2021 . 12 December 2023.
  14. One OI mutation also causes combined Ehler–Danlos syndrome: "OIEDS1". (Cabral|Makareeva|Colige|Letocha|2005}}|Cabral, et al. 2005, Rasmussen|2020}}|Rasmussen 2020)
  15. Cabral WA, Makareeva E, Colige A, Letocha AD, Ty JM, Yeowell HN, Pals G, Leikin S, Marini JC . 6 . Mutations near amino end of alpha1(I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interference with N-propeptide processing . The Journal of Biological Chemistry . 280 . 19 . 19259–19269 . May 2005 . 15728585 . 10.1074/jbc.m414698200 . 17 August 2021 . live . free . https://web.archive.org/web/20210920212533/https://www.jbc.org/article/S0021-9258%2820%2967576-7/fulltext . 20 September 2021 .
  16. Web site: Rasmussen SA. 2020-12-02. Combined osteogenesis imperfecta and Ehlers–Danlos syndrome 1; OIEDS1. live. 2021-08-17. Online Mendelian Inheritance in Man. Johns Hopkins University. 619115. 20 September 2021. https://web.archive.org/web/20210920212532/https://omim.org/entry/619115.
  17. Paterson CR, Monk EA, McAllion SJ . How common is hearing impairment in osteogenesis imperfecta? . The Journal of Laryngology and Otology . 115 . 4 . 280–282 . April 2001 . 11276328 . 10.1258/0022215011907442 . 15 August 2021 . live . 12303464 . https://web.archive.org/web/20210920212539/https://www.cambridge.org/core/journals/journal-of-laryngology-and-otology/article/abs/how-common-is-hearing-impairment-in-osteogenesis-imperfecta/215FADBB8525BC47A658B98F4EE40730 . 20 September 2021 .
  18. Web site: 2005-11-02. OI Issues: Hearing Loss. dead. https://web.archive.org/web/20120120093322/http://www.oif.org/site/PageServer?pagename=HearLoss. 2012-01-20. 4 November 2018. Vernick D.
  19. Santos F, McCall AA, Chien W, Merchant S . Otopathology in Osteogenesis Imperfecta . Otology & Neurotology . 33 . 9 . 1562–1566 . December 2012 . 22996160 . 3498599 . 10.1097/MAO.0b013e31826bf19b .
  20. Pillion JP, Vernick D, Shapiro J . Hearing loss in osteogenesis imperfecta: characteristics and treatment considerations . Genetics Research International . 2011 . 983942 . 2011-12-14 . 22567374 . 3335494 . 10.4061/2011/983942 . . free .
  21. Kuurila K, Grénman R, Johansson R, Kaitila I . Hearing loss in children with osteogenesis imperfecta . European Journal of Pediatrics . 159 . 7 . 515–519 . July 2000 . 10923226 . 10.1007/s004310051322 . 15 August 2021 . live . 8729406 . https://web.archive.org/web/20210815205911/https://link.springer.com/article/10.1007%2Fs004310051322 . 15 August 2021 .
  22. Pillion JP, Shapiro J . Audiological findings in osteogenesis imperfecta . Journal of the American Academy of Audiology . 19 . 8 . 595–601 . September 2008 . 19323351 . 10.3766/jaaa.19.8.3 .
  23. Khandanpour N, Connolly DJ, Raghavan A, Griffiths PD, Hoggard N . Craniospinal abnormalities and neurologic complications of osteogenesis imperfecta: imaging overview . Radiographics . 32 . 7 . 2101–2112 . 2012-12-01 . 23150860 . 10.1148/rg.327125716 . 18 August 2021 . live . https://web.archive.org/web/20210818231827/https://pubmed.ncbi.nlm.nih.gov/23150860/ . 18 August 2021 .
  24. Turkalj M, Miranović V, Lulić-Jurjević R, Gjergja Juraški R, Primorac D. 2017-09-25. Cardiorespiratory complications in patients with osteogenesis imperfecta. Paediatria Croatica. en. 61. 3. 106–111. 1330-1403. 29 August 2021. 20 September 2021. https://web.archive.org/web/20210920212534/https://hrcak.srce.hr/201164. live.
  25. Violas P, Fassier F, Hamdy R, Duhaime M, Glorieux FH. September 2002. Acetabular protrusion in osteogenesis imperfecta. Journal of Pediatric Orthopedics. 22. 5. 622–625. 10.1097/01241398-200209000-00010. 12198464. 37895736.
  26. Lee JH, Gamble JG, Moore RE, Rinsky LA. September 1995. Gastrointestinal problems in patients who have type-III osteogenesis imperfecta. The Journal of Bone and Joint Surgery. American Volume. 77. 9. 1352–1356. 10.2106/00004623-199509000-00010. 7673285.
  27. Sillence DO, Senn A, Danks DM . Genetic heterogeneity in osteogenesis imperfecta . Journal of Medical Genetics . 16 . 2 . 101–116 . April 1979 . 458828 . 1012733 . 10.1136/jmg.16.2.101 .
  28. Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM . Classification of Osteogenesis Imperfecta revisited . European Journal of Medical Genetics . 53 . 1 . 1–5 . 2010-01-01 . 19878741 . 10.1016/j.ejmg.2009.10.007 . 21 August 2021 . live . In 1979 Sillence proposed a classification of Osteogenesis Imperfecta (OI) in OI types I, II, III and IV. In 2004 and 2007 this classification was expanded with OI types V–VIII because of distinct clinical features and/or different causative gene mutations. . https://web.archive.org/web/20210821004559/https://www.sciencedirect.com/science/article/abs/pii/S1769721209001554 . 21 August 2021 .
  29. Web site: McKusick VA, Hamosh A. 2018-10-23. Osteogenesis imperfecta, type I; OI1. live. 2021-08-17. Online Mendelian Inheritance in Man. Johns Hopkins University. en-us. 166200. 26 March 2021. https://web.archive.org/web/20210326192350/https://omim.org/entry/166200.
  30. Marom R, Rabenhorst BM, Morello R . Osteogenesis imperfecta: an update on clinical features and therapies . European Journal of Endocrinology . 183 . 4 . R95–R106 . October 2020 . 32621590 . 7694877 . 10.1530/EJE-20-0299 . 17 August 2021 . live . https://web.archive.org/web/20210817052953/https://eje.bioscientifica.com/view/journals/eje/183/4/EJE-20-0299.xml . 17 August 2021 .
  31. van Dijk FS, Semler O, Etich J, Köhler A, Jimenez-Estrada JA, Bravenboer N, Claeys L, Riesebos E, Gegic S, Piersma SR, Jimenez CR, Waisfisz Q, Flores CL, Nevado J, Harsevoort AJ, Janus GJ, Franken AA, van der Sar AM, Meijers-Heijboer H, Heath KE, Lapunzina P, Nikkels PG, Santen GW, Nüchel J, Plomann M, Wagener R, Rehberg M, Hoyer-Kuhn H, Eekhoff EM, Pals G, Mörgelin M, Newstead S, Wilson BT, Ruiz-Perez VL, Maugeri A, Netzer C, Zaucke F, Micha D . 6 . Interaction between KDELR2 and HSP47 as a Key Determinant in Osteogenesis Imperfecta Caused by Bi-allelic Variants in KDELR2 . American Journal of Human Genetics . 107 . 5 . 989–999 . November 2020 . 33053334 . 7675035 . 10.1016/j.ajhg.2020.09.009 . 29 August 2021 . live . https://web.archive.org/web/20210920212536/https://www.cell.com/ajhg/fulltext/S0002-9297(20)30329-3 . 20 September 2021 .
  32. When year is uncited, OMIM is the source.
  33. Zhytnik L, Maasalu K, Duy BH, Pashenko A, Khmyzov S, Reimann E, Prans E, Kõks S, Märtson A . 6 . De novo and inherited pathogenic variants in collagen-related osteogenesis imperfecta . Molecular Genetics & Genomic Medicine . 7 . 3 . e559 . March 2019 . 30675999 . 6418448 . 10.1002/mgg3.559 .
  34. van Dijk FS, Cobben JM, Kariminejad A, Maugeri A, Nikkels PG, van Rijn RR, Pals G . Osteogenesis Imperfecta: A Review with Clinical Examples . Molecular Syndromology . 2 . 1 . 1–20 . December 2011 . 22570641 . 3343766 . 10.1159/000332228 .
  35. Book: Osteogenesis Imperfecta. StatPearls Publishing. Subramanian S, Viswanathan VK. 2021. StatPearls. 30725642. 30 July 2019. 21 October 2020. https://web.archive.org/web/20201021085017/https://www.ncbi.nlm.nih.gov/books/NBK536957/. live. Last Update: February 3, 2019.
  36. For references for genes for OI types, see the types entry in .
  37. Book: GeneReviews [Internet]]. Steiner RD, Pepin MG, Byers PH, Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP. 2021-05-06. University of Washington, Seattle. Adam MP, Ardinger HH, Pagon RA, etal. COL1A1/2 Osteogenesis Imperfecta. 20301472. 2021-08-26. https://web.archive.org/web/20170118124154/https://www.ncbi.nlm.nih.gov/books/NBK1295/. 18 January 2017. live.
  38. Shapiro JR, Lietman C, Grover M, Lu JT, Nagamani SC, Dawson BC, Baldridge DM, Bainbridge MN, Cohn DH, Blazo M, Roberts TT, Brennen FS, Wu Y, Gibbs RA, Melvin P, Campeau PM, Lee BH . 6 . Phenotypic variability of osteogenesis imperfecta type V caused by an IFITM5 mutation . Journal of Bone and Mineral Research . 28 . 7 . 1523–1530 . July 2013 . 23408678 . 3688672 . 10.1002/jbmr.1891 .
  39. Genetic cause not determined until 2012. (Cho|Lee|Lee|Song|2012}}|Cho, et al. 2012)
  40. Singer RB, Ogston SA, Paterson CR . Mortality in various types of osteogenesis imperfecta . Journal of Insurance Medicine . 33 . 3 . 216–220 . 2001 . 11558400 . 15 August 2021 . live . https://web.archive.org/web/20210815180447/https://pubmed.ncbi.nlm.nih.gov/11558400/ . 15 August 2021 .
  41. Web site: 2021-05-05. Osteogenesis Imperfecta: Types, Symptoms & Management. live. 2021-08-17. Cleveland Clinic. 17 August 2021. https://web.archive.org/web/20210817052938/https://my.clevelandclinic.org/health/diseases/15807-osteogenesis-imperfecta-oi.
  42. Basel D, Steiner RD . Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition . Genetics in Medicine . 11 . 6 . 375–385 . June 2009 . 19533842 . 10.1097/GIM.0b013e3181a1ff7b . 19 August 2021 . live . free . https://web.archive.org/web/20210920212534/https://www.nature.com/articles/gim200954.pdf?origin=ppub&error=cookies_not_supported&code=25b1628f-762d-41d4-a9ed-906855f1314c . 20 September 2021 .
  43. Nadar R, Saraff V, Hogler W, Desai M, Shaw N. 2019-07-31. Determinants of survival in osteogenesis imperfecta (OI) Type II. Bone Abstracts. 7. 31. 10.1530/boneabs.7.P31. 208412310. 2052-1219. 19 August 2021. 20 September 2021. https://web.archive.org/web/20210920212536/https://www.bone-abstracts.org/ba/0007/ba0007p31.htm. live.
  44. Zisa D, Shabbir A, Mastri M, Suzuki G, Lee T . Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells . American Journal of Physiology. Regulatory, Integrative and Comparative Physiology . 297 . 5 . R1503–R1515 . November 2009 . 19759338 . 2777764 . 10.1152/ajpregu.00227.2009 .
  45. Ben Amor IM, Glorieux FH, Rauch F . Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta . Journal of Osteoporosis . 2011 . 540178 . 2011-09-06 . 21912751 . 3170785 . 10.4061/2011/540178 . For example, it can occur that a fetus is diagnosed with OI type II, the lethal form, on prenatal ultrasound, but after birth turns out to be less severely affected than initially thought and is eventually reclassified as OI type III or even type VI, if adequate management is initiated early on. . free .
  46. Georgescu I, Vlad C, Gavriliu TŞ, Dan S, Pârvan AA . Surgical treatment in Osteogenesis Imperfecta - 10 years experience . Journal of Medicine and Life . 6 . 2 . 205–213 . June 2013 . 23904885 . 3725451 .
  47. Book: Atlas of genetic diagnosis and counseling. Chen H. Humana Press. 2006. 978-1-58829-681-8. Totowa, NJ. 771. Triangular face. https://books.google.com/books?id=2VcdAXJ_dZkC&pg=PA771. https://web.archive.org/web/20130608031238/http://books.google.com/books?id=2VcdAXJ_dZkC&pg=PA771. 8 June 2013.
  48. Book: Osteogenesis imperfecta: a translational approach to brittle bone disease. Shapiro JR, Byers PH, Glorieux FH, Sponseller PD. Elsevier Inc.. 2014. 978-0-12-397165-4. 2nd. London. 876364090.
  49. Johnson MT, Morrison S, Heeger S, Mooney S, Byers PH, Robin NH . A variant of osteogenesis imperfecta type IV with resolving kyphomelia is caused by a novel COL1A2 mutation . Journal of Medical Genetics . 39 . 2 . 128–132 . February 2002 . 11836364 . 1735034 . 10.1136/jmg.39.2.128 . The persistent pale blue sclera is uncommon in OI type IV, but can be seen in up to 10% of affected subjects. .
  50. Van Dijk FS, Sillence DO . Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment . American Journal of Medical Genetics. Part A . 164A . 6 . 1470–1481 . June 2014 . 24715559 . 4314691 . 10.1002/ajmg.a.36545 .
  51. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F, Bishop NJ . 6 . Type V osteogenesis imperfecta: a new form of brittle bone disease . Journal of Bone and Mineral Research . 15 . 9 . 1650–1658 . September 2000 . 10976985 . 10.1359/jbmr.2000.15.9.1650 . 13748803 .
  52. Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, Lee G, Kim HN, Lee HR, Eom HH, Lee ZH, Kim OH, Park WY, Park SS, Ikegawa S, Yoo WJ, Choi IH, Kim JW . 6 . A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V . American Journal of Human Genetics . 91 . 2 . 343–348 . August 2012 . 22863190 . 3415533 . 10.1016/j.ajhg.2012.06.005 .
  53. Cao YJ, Wei Z, Zhang H, Zhang ZL . Expanding the Clinical Spectrum of Osteogenesis Imperfecta Type V: 13 Additional Patients and Review . Frontiers in Endocrinology . 10 . 375 . 2019-06-12 . 31244780 . 6581704 . 10.3389/fendo.2019.00375 . free .
  54. Brizola E, Mattos EP, Ferrari J, Freire PO, Germer R, Llerena JC, Félix TM . Clinical and Molecular Characterization of Osteogenesis Imperfecta Type V . english . Molecular Syndromology . 6 . 4 . 164–172 . October 2015 . 26648832 . 4662268 . 10.1159/000439506 .
  55. Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, Castagnola P, Rauch F, Glorieux FH, Vranka J, Bächinger HP, Pace JM, Schwarze U, Byers PH, Weis M, Fernandes RJ, Eyre DR, Yao Z, Boyce BF, Lee B . 6 . CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta . Cell . 127 . 2 . 291–304 . October 2006 . 17055431 . 10.1016/j.cell.2006.08.039 . 8123837 . free .
  56. Barnes AM, Chang W, Morello R, Cabral WA, Weis M, Eyre DR, Leikin S, Makareeva E, Kuznetsova N, Uveges TE, Ashok A, Flor AW, Mulvihill JJ, Wilson PL, Sundaram UT, Lee B, Marini JC . 6 . Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta . The New England Journal of Medicine . 355 . 26 . 2757–2764 . December 2006 . 17192541 . 7509984 . 10.1056/NEJMoa063804 .
  57. Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, Makareeva E, Kuznetsova NV, Rosenbaum KN, Tifft CJ, Bulas DI, Kozma C, Smith PA, Eyre DR, Marini JC . 6 . Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta . Nature Genetics . 39 . 3 . 359–365 . March 2007 . 17277775 . 7510175 . 10.1038/ng1968 .
  58. van Dijk FS, Nesbitt IM, Zwikstra EH, Nikkels PG, Piersma SR, Fratantoni SA, Jimenez CR, Huizer M, Morsman AC, Cobben JM, van Roij MH, Elting MW, Verbeke JI, Wijnaendts LC, Shaw NJ, Högler W, McKeown C, Sistermans EA, Dalton A, Meijers-Heijboer H, Pals G . 6 . PPIB mutations cause severe osteogenesis imperfecta . American Journal of Human Genetics . 85 . 4 . 521–527 . October 2009 . 19781681 . 2756556 . 10.1016/j.ajhg.2009.09.001 .
  59. Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M, Alrasheed S, Pepin MG, Weis MA, Eyre DR, Byers PH . 6 . Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta . American Journal of Human Genetics . 86 . 3 . 389–398 . March 2010 . 20188343 . 2833387 . 10.1016/j.ajhg.2010.01.034 .
  60. Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, Aktas D, Alikasifoglu M, Tuncbilek E, Orhan D, Bakar FT, Zabel B, Superti-Furga A, Bruckner-Tuderman L, Curry CJ, Pyott S, Byers PH, Eyre DR, Baldridge D, Lee B, Merrill AE, Davis EC, Cohn DH, Akarsu N, Krakow D . 6 . Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta . American Journal of Human Genetics . 86 . 4 . 551–559 . April 2010 . 20362275 . 2850430 . 10.1016/j.ajhg.2010.02.022 .
  61. Sam JE, Dharmalingam M . Osteogenesis Imperfecta . Indian Journal of Endocrinology and Metabolism . 21 . 6 . 903–908 . 2017 . 29285457 . 5729682 . 10.4103/ijem.IJEM_220_17 . free .
  62. Book: Shapiro JR . Clinical and Genetic Classification of Osteogenesis Imperfecta and Epidemiology. 2014. 15–22. Elsevier. 9780123971654. 10.1016/b978-0-12-397165-4.00002-2. Osteogenesis Imperfecta.
  63. Sam JE, Dharmalingam M . Osteogenesis Imperfecta . Indian Journal of Endocrinology and Metabolism . 21 . 6 . 903–908 . 2017-11-01 . 29285457 . 5729682 . 10.4103/ijem.IJEM_220_17 . free .
  64. Shaheen R, Alazami AM, Alshammari MJ, Faqeih E, Alhashmi N, Mousa N, Alsinani A, Ansari S, Alzahrani F, Al-Owain M, Alzayed ZS, Alkuraya FS . 6 . Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation . Journal of Medical Genetics . 49 . 10 . 630–635 . October 2012 . 23054245 . 10.1136/jmedgenet-2012-101142 . 35542661 .
  65. Lindahl K, Åström E, Dragomir A, Symoens S, Coucke P, Larsson S, Paschalis E, Roschger P, Gamsjaeger S, Klaushofer K, Fratzl-Zelman N, Kindmark A . 6 . Homozygosity for CREB3L1 premature stop codon in first case of recessive osteogenesis imperfecta associated with OASIS-deficiency to survive infancy . Bone . 114 . 268–277 . September 2018 . 29936144 . 10.1016/j.bone.2018.06.019 . 29 August 2021 . live . 49406925 . https://web.archive.org/web/20210829024252/https://www.sciencedirect.com/science/article/abs/pii/S8756328218302515 . 29 August 2021 .
  66. Keller RB, Tran TT, Pyott SM, Pepin MG, Savarirayan R, McGillivray G, Nickerson DA, Bamshad MJ, Byers PH . 6 . Monoallelic and biallelic CREB3L1 variant causes mild and severe osteogenesis imperfecta, respectively . Genetics in Medicine . 20 . 4 . 411–419 . April 2018 . 28817112 . 5816725 . 10.1038/gim.2017.115 .
  67. Mendoza-Londono R, Fahiminiya S, Majewski J, Tétreault M, Nadaf J, Kannu P, Sochett E, Howard A, Stimec J, Dupuis L, Roschger P, Klaushofer K, Palomo T, Ouellet J, Al-Jallad H, Mort JS, Moffatt P, Boudko S, Bächinger HP, Rauch F . 6 . Recessive osteogenesis imperfecta caused by missense mutations in SPARC . American Journal of Human Genetics . 96 . 6 . 979–985 . June 2015 . 26027498 . 4457955 . 10.1016/j.ajhg.2015.04.021 .
  68. Doyard M, Bacrot S, Huber C, Di Rocco M, Goldenberg A, Aglan MS, Brunelle P, Temtamy S, Michot C, Otaify GA, Haudry C, Castanet M, Leroux J, Bonnefont JP, Munnich A, Baujat G, Lapunzina P, Monnot S, Ruiz-Perez VL, Cormier-Daire V . 6 . FAM46A mutations are responsible for autosomal recessive osteogenesis imperfecta . Journal of Medical Genetics . 55 . 4 . 278–284 . April 2018 . 29358272 . 10.1136/jmedgenet-2017-104999 . 29 August 2021 . . live . 4283476 . https://web.archive.org/web/20210829024310/https://jmg.bmj.com/content/55/4/278 . 29 August 2021 .
  69. Moosa S, Yamamoto GL, Garbes L, Keupp K, Beleza-Meireles A, Moreno CA, Valadares ER, de Sousa SB, Maia S, Saraiva J, Honjo RS, Kim CA, Cabral de Menezes H, Lausch E, Lorini PV, Lamounier A, Carniero TC, Giunta C, Rohrbach M, Janner M, Semler O, Beleggia F, Li Y, Yigit G, Reintjes N, Altmüller J, Nürnberg P, Cavalcanti DP, Zabel B, Warman ML, Bertola DR, Wollnik B, Netzer C . 6 . Autosomal-Recessive Mutations in MESD Cause Osteogenesis Imperfecta . American Journal of Human Genetics . 105 . 4 . 836–843 . October 2019 . 31564437 . 6817720 . 10.1016/j.ajhg.2019.08.008 .
  70. Byers PH, Pyott SM. 2012-12-15. Recessively Inherited Forms of Osteogenesis Imperfecta. Annual Review of Genetics. en. 46. 1. 475–497. 10.1146/annurev-genet-110711-155608. 23145505. 0066-4197. subscription.
  71. Ho Duy B, Zhytnik L, Maasalu K, Kändla I, Prans E, Reimann E, Märtson A, Kõks S . 6 . Mutation analysis of the COL1A1 and COL1A2 genes in Vietnamese patients with osteogenesis imperfecta . Human Genomics . 10 . 1 . 27 . August 2016 . 27519266 . 4983065 . 10.1186/s40246-016-0083-1 . free .
  72. Palomo T, Vilaça T, Lazaretti-Castro M . Osteogenesis imperfecta: diagnosis and treatment . Current Opinion in Endocrinology, Diabetes and Obesity . 24 . 6 . 381–388 . December 2017 . 28863000 . 10.1097/MED.0000000000000367 . 4555427 .
  73. Valadares ER, Carneiro TB, Santos PM, Oliveira AC, Zabel B . What is new in genetics and osteogenesis imperfecta classification? . Jornal de Pediatria . 90 . 6 . 536–541 . 18 July 2014 . 25046257 . 10.1016/j.jped.2014.05.003 . free .
  74. Forlino A, Cabral WA, Barnes AM, Marini JC . New perspectives on osteogenesis imperfecta . Nature Reviews. Endocrinology . 7 . 9 . 540–557 . June 2011 . 21670757 . 3443407 . 10.1038/nrendo.2011.81 .
  75. Forlino A, Marini JC . Osteogenesis imperfecta . Lancet . 387 . 10028 . 1657–1671 . April 2016 . 26542481 . 7384887 . 10.1016/S0140-6736(15)00728-X .
  76. Koromani F, Trajanoska K, Rivadeneira F, Oei L . Recent Advances in the Genetics of Fractures in Osteoporosis . English . Frontiers in Endocrinology . 10 . 337 . 2019-06-04 . 31231309 . 6559287 . 10.3389/fendo.2019.00337 . free .
  77. Rohrbach M, Giunta C . Recessive osteogenesis imperfecta: clinical, radiological, and molecular findings . American Journal of Medical Genetics. Part C, Seminars in Medical Genetics . 160C . 3 . 175–189 . August 2012 . 22791419 . 10.1002/ajmg.c.31334 . 28592112 . free .
  78. Marini JC, Blissett AR . New genes in bone development: what's new in osteogenesis imperfecta . The Journal of Clinical Endocrinology and Metabolism . 98 . 8 . 3095–3103 . August 2013 . 23771926 . 3733862 . 10.1210/jc.2013-1505 .
  79. Marini JC, Reich A, Smith SM . Osteogenesis imperfecta due to mutations in non-collagenous genes: lessons in the biology of bone formation . Current Opinion in Pediatrics . 26 . 4 . 500–507 . August 2014 . 25007323 . 4183132 . 10.1097/MOP.0000000000000117 .
  80. Hanagata N . IFITM5 mutations and osteogenesis imperfecta . Journal of Bone and Mineral Metabolism . 34 . 2 . 123–131 . March 2016 . 26031935 . 10.1007/s00774-015-0667-1 . 3173191 .
  81. Lindert U, Cabral WA, Ausavarat S, Tongkobpetch S, Ludin K, Barnes AM, Yeetong P, Weis M, Krabichler B, Srichomthong C, Makareeva EN, Janecke AR, Leikin S, Röthlisberger B, Rohrbach M, Kennerknecht I, Eyre DR, Suphapeetiporn K, Giunta C, Marini JC, Shotelersuk V . 6 . MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta . Nature Communications . 7 . 1 . 11920 . July 2016 . 27380894 . 4935805 . 10.1038/ncomms11920 . 2016NatCo...711920L .
  82. Pyott SM, Pepin MG, Schwarze U, Yang K, Smith G, Byers PH . Recurrence of perinatal lethal osteogenesis imperfecta in sibships: parsing the risk between parental mosaicism for dominant mutations and autosomal recessive inheritance . Genetics in Medicine . 13 . 2 . 125–130 . February 2011 . 21239989 . 10.1097/GIM.0b013e318202e0f6 . free .
  83. Rauch F, Glorieux FH . Osteogenesis imperfecta . Lancet . 363 . 9418 . 1377–1385 . April 2004 . 15110498 . 10.1016/S0140-6736(04)16051-0 . 24081895 .
  84. Gautieri A, Uzel S, Vesentini S, Redaelli A, Buehler MJ . Molecular and mesoscale mechanisms of osteogenesis imperfecta disease in collagen fibrils . Biophysical Journal . 97 . 3 . 857–865 . August 2009 . 19651044 . 2718154 . 10.1016/j.bpj.2009.04.059 . 2009BpJ....97..857G .
  85. Xiao J, Cheng H, Silva T, Baum J, Brodsky B . Osteogenesis imperfecta missense mutations in collagen: structural consequences of a glycine to alanine replacement at a highly charged site . Biochemistry . 50 . 50 . 10771–10780 . December 2011 . 22054507 . 3292618 . 10.1021/bi201476a .
  86. Nijhuis WH, Eastwood DM, Allgrove J, Hvid I, Weinans HH, Bank RA, Sakkers RJ . Current concepts in osteogenesis imperfecta: bone structure, biomechanics and medical management . Journal of Children's Orthopaedics . 13 . 1 . 1–11 . February 2019 . 30838070 . 6376438 . 10.1302/1863-2548.13.180190 .
  87. El-Sobky TA, Shawky RM, Sakr HM, Elsayed SM, Elsayed NS, Ragheb SG, Gamal R . A systematized approach to radiographic assessment of commonly seen genetic bone diseases in children: A pictorial review.. J Musculoskelet Surg Res. 1. 2. 25. 15 November 2017. 10.4103/jmsr.jmsr_28_17. 79825711 . free .
  88. Book: 3D micron-scale imaging of the cortical bone canal network in human osteogenesis imperfecta (OI) . Jameson JR, Albert CI, Busse B, Smith PA, Harris GF . Weaver JB, Molthen RC . Medical Imaging 2013: Biomedical Applications in Molecular, Structural, and Functional Imaging . March 29, 2013 . International Society for Optics and Photonics . 8672 . 86721L . 10.1117/12.2007209 . 13876569 . 26 August 2020 . 7 June 2020 . https://web.archive.org/web/20200607062934/https://epublications.marquette.edu/bioengin_fac/470/ . live .
  89. Westgren M, Götherström C . Stem cell transplantation before birth - a realistic option for treatment of osteogenesis imperfecta? . Prenatal Diagnosis . 35 . 9 . 827–832 . September 2015 . 25962526 . 10.1002/pd.4611 . 10640427 .
  90. Pepin MG, Byers PH . What every clinical geneticist should know about testing for osteogenesis imperfecta in suspected child abuse cases . American Journal of Medical Genetics. Part C, Seminars in Medical Genetics . 169 . 4 . 307–313 . December 2015 . 26566591 . 10.1002/ajmg.c.31459 . 26045033 .
  91. News: 2005-10-25. Parents Get $1 Million in False Abuse Case. en-US. Washington Post. 2022-02-04. 0190-8286. Castaneda R.
  92. Web site: What Is Osteogenesis Imperfecta? Fast Facts: An Easy-to-Read Series of Publications for the Public. NIAMS. 15 October 2016. November 2014. live. https://web.archive.org/web/20161018215941/http://www.niams.nih.gov/Health_Info/Bone/Osteogenesis_Imperfecta/osteogenesis_imperfecta_ff.asp. 18 October 2016.
  93. Swezey T, Reeve BB, Hart TS, Floor MK, Dollar CM, Gillies AP, Tosi LL . Incorporating the patient perspective in the study of rare bone disease: insights from the osteogenesis imperfecta community . Osteoporosis International . 30 . 2 . 507–511 . February 2019 . 30191258 . 6449303 . 10.1007/s00198-018-4690-7 .
  94. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R . Cyclic administration of pamidronate in children with severe osteogenesis imperfecta . The New England Journal of Medicine . 339 . 14 . 947–952 . October 1998 . 9753709 . 10.1056/NEJM199810013391402 . 19316414 . free . Free full text
  95. DiMeglio LA, Peacock M . Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta . Journal of Bone and Mineral Research . 21 . 1 . 132–140 . January 2006 . 16355282 . 10.1359/JBMR.051006 . 12996685 . free .
  96. Bishop N, Adami S, Ahmed SF, Antón J, Arundel P, Burren CP, Devogelaer JP, Hangartner T, Hosszú E, Lane JM, Lorenc R, Mäkitie O, Munns CF, Paredes A, Pavlov H, Plotkin H, Raggio CL, Reyes ML, Schoenau E, Semler O, Sillence DO, Steiner RD . 6 . Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial . Lancet . 382 . 9902 . 1424–1432 . October 2013 . 23927913 . 10.1016/S0140-6736(13)61091-0 . 25559791 .
  97. Ward LM, Rauch F . Oral bisphosphonates for paediatric osteogenesis imperfecta? . Lancet . 382 . 9902 . 1388–1389 . October 2013 . 23927912 . 10.1016/S0140-6736(13)61531-7 . 5872511 .
  98. Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, Garnero P, Arlot M, Raynal C, Meunier PJ . 6 . Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial . Journal of Bone and Mineral Research . 21 . 2 . 300–306 . February 2006 . 16418786 . 10.1359/JBMR.051015 . 34089615 . free .
  99. Meena BL, Panigrahi I, Marwaha RK. 2014-10-01. PO-0077 Vitamin D Deficiency In Children With Osteogenesis Imperfecta. Archives of Disease in Childhood. en. 99. Suppl 2. A275. 10.1136/archdischild-2014-307384.747. 72491188. 0003-9888. 18 September 2021. 18 September 2021. https://web.archive.org/web/20210918102054/https://adc.bmj.com/content/99/Suppl_2/A275.1. live. free.
  100. Edouard T, Glorieux FH, Rauch F . Predictors and correlates of vitamin D status in children and adolescents with osteogenesis imperfecta . The Journal of Clinical Endocrinology and Metabolism . 96 . 10 . 3193–3198 . October 2011 . 21832107 . 10.1210/jc.2011-1480 . free .
  101. Zambrano MB, Brizola E, Pinheiro B, Vanz AP, Mello ED, Félix TM . Study of the Determinants of Vitamin D Status in Pediatric Patients With Osteogenesis Imperfecta . Journal of the American College of Nutrition . 35 . 4 . 339–345 . 2016-05-18 . 26709914 . 10.1080/07315724.2015.1057776 . 45930763 .
  102. Rothschild L, Goeller JK, Voronov P, Barabanova A, Smith P . Anesthesia in children with osteogenesis imperfecta: Retrospective chart review of 83 patients and 205 anesthetics over 7 years . Pediatric Anesthesia . 28 . 11 . 1050–1058 . November 2018 . 30295359 . 10.1111/pan.13504 . 29 August 2021 . live . 52929810 . https://web.archive.org/web/20210829064208/https://onlinelibrary.wiley.com/doi/10.1111/pan.13504 . 29 August 2021 .
  103. Book: Handbook of Pediatric Anesthesia. Houck JP. McGraw-Hill Education. 2014. 9780071769358. Houck JP, Hache M, Sun LS. New York. Osteogenesis imperfecta. https://accessanesthesiology.mhmedical.com/content.aspx?sectionid=70364025&bookid=1189. 29 August 2021. 29 August 2021. https://web.archive.org/web/20210829064222/https://accessanesthesiology.mhmedical.com/content.aspx?sectionid=70364025&bookid=1189. live.
  104. Web site: Financial Assistance. live. https://web.archive.org/web/20210303085312/https://www.shrinershospitalsforchildren.org/shc/financial-assistance. 2021-03-03. 2021-08-21. Shriners Hospitals for Children. Shriners Hospitals for Children is committed to providing specialized care to children with orthopaedic conditions [...] regardless of the families' ability to pay..
  105. Web site: A Leader in the Treatment of Osteogensis Imperfecta (OI). dead. https://web.archive.org/web/20070928140354/http://www.shriners.com/Hospitals/Chicago/conditions/OI.aspx. 2007-09-28. 2007-07-05. Shriners International.
  106. Sofield HA, Millar EA . 1959-12-01. Fragmentation, Realignment, and Intramedullary Rod Fixation of Deformities of the Long Bones in Children: A Ten-Year Appraisal . The Journal of Bone and Joint Surgery. en-US. 41. 8. 1371–1391. 10.2106/00004623-195941080-00001. 0021-9355.
  107. Rodriguez Celin M, Kruger KM, Caudill A, Nagamani SC, Harris GF, Smith PA . A Multicenter Study of Intramedullary Rodding in Osteogenesis Imperfecta . JB & JS Open Access . 5 . 3 . e20.00031 . 2020-09-11 . 32984750 . 7489747 . 10.2106/JBJS.OA.20.00031 .
  108. Web site: The Fassier-Duval Telescopic IM System. live. 2021-08-15. Pega Medical. Laval, Quebec. en. 15 August 2021. https://web.archive.org/web/20210815171101/https://www.pegamedical.com/en/products/the-fassier-duval-telescopic-im-system.
  109. Sterian A, Balanescu R, Barbilian A, Ulici A . Osteosynthesis in Osteogenesis Imperfecta, telescopic versus non-telescopic nailing . Journal of Medicine and Life . 8 . 4 . 563–565 . 2015 . 26664490 . 4656972 .
  110. Web site: Frassier F, Duval P, Paley D. 2021. Fassier–Duval Telescopic IM System Surgical Technique. live. 2021-08-15. Pega Medical. Laval, Quebec. FD-ST-EN Revision K. 15 August 2021. https://web.archive.org/web/20210815171101/https://www.pegamedical.com/medias/iw/FD-ST-EN-RevK_1.pdf.
  111. Belyea CM, Knox JB . 2020-01-01. Spinal fusion in children with osteogenesis imperfecta: A nationwide retrospective comparative cohort study over a 12-year period. Current Orthopaedic Practice. en-US. 31. 1. 72–75. 10.1097/BCO.0000000000000805. 209229412. 1940-7041.
  112. Wallace MJ, Kruse RW, Shah SA . The Spine in Patients With Osteogenesis Imperfecta . The Journal of the American Academy of Orthopaedic Surgeons . 25 . 2 . 100–109 . February 2017 . 28009707 . 10.5435/JAAOS-D-15-00169 .
  113. Zani A, Ford-Adams M, Ratcliff M, Bevan D, Inge TH, Desai A . Weight loss surgery improves quality of life in pediatric patients with osteogenesis imperfecta . Surgery for Obesity and Related Diseases . 13 . 1 . 41–44 . January 2017 . 26948942 . 5965274 . 10.1016/j.soard.2015.11.029 . .
  114. Semler O, Fricke O, Vezyroglou K, Stark C, Schoenau E . Preliminary results on the mobility after whole body vibration in immobilized children and adolescents . Journal of Musculoskeletal & Neuronal Interactions . 7 . 1 . 77–81 . 2007-01-01 . 17396011 . 18 August 2021 . live . https://web.archive.org/web/20210818230057/https://pubmed.ncbi.nlm.nih.gov/17396011/ . 18 August 2021 .
  115. Biria M, Abbas FM, Mozaffar S, Ahmadi R . Dentinogenesis imperfecta associated with osteogenesis imperfecta . Dental Research Journal . 9 . 4 . 489–494 . July 2012 . 23162594 . 3491340 .
  116. Web site: 2020-12-18. Recycling pays off for Mereo. live. 2021-09-18. Evaluate Vantage. en. Plieth J. 18 September 2021. https://web.archive.org/web/20210918091906/https://www.evaluate.com/vantage/articles/news/deals/recycling-pays-mereo.
  117. Delgado-Calle J, Sato AY, Bellido T . Role and mechanism of action of sclerostin in bone . Bone . 96 . 29–37 . March 2017 . 27742498 . 5328835 . 10.1016/j.bone.2016.10.007 .
  118. Glorieux FH, Devogelaer JP, Durigova M, Goemaere S, Hemsley S, Jakob F, Junker U, Ruckle J, Seefried L, Winkle PJ . 6 . BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial . Journal of Bone and Mineral Research . 32 . 7 . 1496–1504 . July 2017 . 28370407 . 10.1002/jbmr.3143 . 4432023 . free .
  119. Web site: 2020-12-17. Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta. live. 2021-09-18. Ultragenyx Pharmaceutical Inc.. en. 18 September 2021. https://web.archive.org/web/20210918094909/https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-and-mereo-biopharma-announce-collaboration-and.
  120. 2021-04-01 . A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 (ASTEROID). 2021-09-18. ClinicalTrials.gov. United States National Library of Medicine. NCT03118570.
  121. Web site: 2019-11-25. Setrusumab ready to advance into pivotal studies. live. 2021-09-18. Trinity Delta. en-US. Cooper M, Gregorek L. 18 September 2021. https://web.archive.org/web/20210918104032/https://www.trinitydelta.org/research-notes/setrusumab-ready-to-advance-into-pivotal-studies/.
  122. Web site: 2020-09-24. Mereo setrusumab gets FDA rare pediatric disease designation for osteogenesis imperfecta. live. 2021-09-18. BioTuesdays. en-CA. Hardy A. 18 September 2021. https://web.archive.org/web/20210918090404/https://biotuesdays.com/2020/09/24/mereo-setrusumab-gets-fda-rare-pediatric-disease-designation-for-osteogenesis-imperfecta/.
  123. 2021-07-23 . Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta. live. 2021-09-18. ClinicalTrials.gov. United States National Library of Medicine. NCT04545554. 18 September 2021. https://web.archive.org/web/20210918105332/https://clinicaltrials.gov/ct2/show/NCT04545554.
  124. Web site: Out of Ignorance . 2022-09-02 . Ultragenyx Stock: Downward Trajectory Likely to Continue . 2022-09-24 . . en.
  125. Web site: Carpenter . Thomas . Gulanski . Barbara . Barros . Julio Sotto . vanc . 2023-04-21 . Study to Assess the Efficacy and Safety of Setrusumab in Participants With Osteogenesis Imperfecta . https://web.archive.org/web/20230726062924/https://www.yalemedicine.org/clinical-trials/efficacy-and-safety-of-setrusumab-in-subjects-with-osteogenesis-imperfecta-1 . 2023-07-26 . 2023-12-16 . Yale Medicine . en.
  126. Web site: Green R . 2012-03-11. Brittle Bone Disease Forced Mother Into 'No Easy Choice'. 2021-09-16. Hartford Courant. en-US.
  127. News: Hopper T . 2013-02-06. 'Incompatible with life': Mother's account of her difficult decision to request a late-term abortion sheds light on 'live-born' debate. 2021-09-16. National Post. en-CA.
  128. Folkestad L, Hald JD, Canudas-Romo V, Gram J, Hermann AP, Langdahl B, Abrahamsen B, Brixen K . 6 . Mortality and Causes of Death in Patients With Osteogenesis Imperfecta: A Register-Based Nationwide Cohort Study . Journal of Bone and Mineral Research . 31 . 12 . 2159–2166 . December 2016 . 27345018 . 10.1002/jbmr.2895 . 32196304 . free .
  129. Paterson CR, Ogston SA, Henry RM . Life expectancy in osteogenesis imperfecta . BMJ . 312 . 7027 . 351 . February 1996 . 8611834 . 2350292 . 10.1136/bmj.312.7027.351 .
  130. Book: Donohoe M . Osteogenesis Imperfecta. Therapy, Orthotics and Assistive Devices for Osteogenesis Imperfecta. 2020. http://link.springer.com/10.1007/978-3-030-42527-2_3. Osteogenesis Imperfecta: A Case-Based Guide to Surgical Decision-Making and Care. 21–37. Kruse RW . Springer International Publishing. en. 10.1007/978-3-030-42527-2_3. 978-3-030-42526-5. 219518604.
  131. Web site: Genetics of Osteogenesis Imperfecta . https://web.archive.org/web/20101230211602/http://emedicine.medscape.com/article/947588-overview . 2010-12-30 . Plotkin H . 29 February 2016 .
  132. Book: Bone Health and Osteoporosis: A Report of the Surgeon General. Office of the Surgeon General of the United States, U.S. Department of Health and Human Services. 2004. Rockville, Maryland. 68. en. 2.4: The Frequency of Bone Disease. WE 225 B71259 2004. https://www.ncbi.nlm.nih.gov/books/NBK45515/.
  133. Web site: Osteogenesis Imperfecta Panel. dead. 2019-07-30. University of Nebraska Medical Center. 30 July 2019. https://web.archive.org/web/20190730080719/https://www.unmc.edu/mmi/geneticslab/catalog/postnatal-testing/post-p-oi.html.
  134. 6. Abali S, Arman A, Atay Z, Bereket A, Bas S, Haliloglu B, Guran T, Gormez Z, Demirci H, Akarsu N, Turan S. 2016-08-19. Frequency of Recessive Osteogenesis Imperfecta in a Turkish Cohort and Genetic Causes. ESPE Abstracts. en. Bioscientifica. 86. 131. 26 August 2021. 26 August 2021. https://web.archive.org/web/20210826081612/https://abstracts.eurospe.org/hrp/0086/hrp0086p1-p131. live.
  135. Book: The brittle bone syndrome: osteogenesis imperfecta. Roger S, Francis MJ, Houghton GR. Butterworth-Heinemann. 1983. 978-0-407-00211-1. London. 4. 9784850.
  136. Lowenstein EJ . Osteogenesis imperfecta in a 3,000-year-old mummy . Child's Nervous System . 25 . 5 . 515–516 . May 2009 . 19212769 . 10.1007/s00381-009-0817-7 . free .
  137. Tainmont J . History of osteogenesis imperfecta or brittle bone disease: a few stops on a road 3000 years long . B-Ent . 3 . 3 . 157–173 . 2007 . 17970442 . 29 August 2021 . live . https://web.archive.org/web/20210829002652/http://www.b-ent.be/en/a-historical-vignette-be-proud-of-yourself-you-have-a-history-history-of-osteogenesis-imperfecta-or-brittle-bone-disease-a-few-stops-on-a-road-3000-years-long-16829 . 29 August 2021 .
  138. Web site: Groeneveld E. 2018-11-12. Ivar the Boneless. live. https://web.archive.org/web/20210821165537/https://www.worldhistory.org/Ivar_the_Boneless/. 2021-08-21. 2021-08-21. World History Encyclopedia. Ancient History Encyclopedia Limited. en.
  139. Web site: Lewis R, Lotha G, Gaur A. 2019-01-08. Ivar the Boneless. live. 2021-08-21. Encyclopedia Britannica. en. 24 June 2021. https://web.archive.org/web/20210624065051/https://www.britannica.com/biography/Ivar-the-Boneless.
  140. Book: Dang Do AN, Marini JC. 2021-01-27. John Wiley & Sons. 978-1-119-43267-8. Carey JC, Cassidy SB, Battaglia A, Viskochil D. 683–705. en. Osteogenesis imperfecta. https://books.google.com/books?id=B7cAEAAAQBAJ&pg=PA683. 29 August 2021. 29 August 2021. https://web.archive.org/web/20210829002647/https://books.google.com/books?id=B7cAEAAAQBAJ&pg=PA683&lpg=PA683. live.
  141. De la recherche de la vérité. Malebranche N . Nicolas Malebranche. 1688. Page:Malebranche_-_De_la_recherche_de_la_vérité.djvu/140. fr. 119. 1842.
  142. Edelu B, Ndu I, Asinobi I, Obu H, Adimora G . Osteogenesis imperfecta: a case report and review of literature . Annals of Medical and Health Sciences Research . 4 . Suppl 1 . S1–S5 . March 2014 . 25031897 . 4083720 . 10.4103/2141-9248.131683 . . free .
  143. Hektoen L. May 1903. Anatomical Study of a Short-Limbed Dwarf, With Special Reference To Osteogenesis Imperfecta and Chondrodystrophia Foetalis. The American Journal of the Medical Sciences. J. B. Lippincott & Co.. 125. 5. 751–769. 10.1097/00000441-190305000-00001. 978-0-243-38392-4. 71836609. 16 August 2021. 16 August 2021. https://web.archive.org/web/20210816123354/https://books.google.com/books?id=DOxGAQAAMAAJ&pg=PA763. live.
  144. Davel JG, Fichardt T, Van Der Spuy D . Osteogenesis imperfecta . Archives of Disease in Childhood . 31 . 159 . 346–353 . October 1956 . 13363481 . 2011939 . 10.1136/adc.31.159.346 .
  145. Adair-Dighton CA. 1912. Four generations of blue sclerotics. The Ophthalmoscope. London. George Pulman & Sons, Ltd. 10. 188–189. 1049881577. Internet Archive.
  146. Book: la|Tabulae ad illustrandam embryogenesin hominis et mammalium, tam naturalem quam abnormem — nl|De Vrucht van den Mensch en van de Zoogdieren afgebeeld en beschreven in hare regelmatige en onregelmatige Ontwikkeling. Vrolik W. G.M.P. Londonck. 1849. Amsterdam. 562–566. la, nl. Illustrations of human and mammalian embryogenesis, both normal and abnormal. 489920691. 29 August 2021. 29 August 2021. https://web.archive.org/web/20210829002655/https://objects.library.uu.nl/reader/index.php?obj=1874-282727&lan=en#page//13/18/68/131868320076759297610882234672017577930.jpg/mode/1up. live.
  147. Baljet B . Aspects of the history of osteogenesis imperfecta (Vrolik's syndrome) . Annals of Anatomy - Anatomischer Anzeiger . 184 . 1 . 1–7 . January 2002 . 11876477 . 10.1016/S0940-9602(02)80023-1 . 29 August 2021 . live . https://web.archive.org/web/20180612014557/https://linkinghub.elsevier.com/retrieve/pii/S0940960202800231 . 12 June 2018 .
  148. Book: Baljet B. Geschichte der Grenzgebiete der Orthopädie . Verlag Theodor Steinkopff. 2002. 978-3-642-57510-5. Rauschmann MA, Thomann KD, Zichner, L. 4. Heidelberg. 133–144. Willem Vrolik and "his" Syndrome. 10.1007/978-3-642-57510-5_15. https://link.springer.com/chapter/10.1007/978-3-642-57510-5_15. 29 August 2021. 8 June 2018. https://web.archive.org/web/20180608065057/https://link.springer.com/chapter/10.1007%2F978-3-642-57510-5_15. live.
  149. Looser E. 1906. Zur Kenntnis der Osteogenesis Imperfecta Congenita et Tarda (sogenannte idiopathische Osteopsatyrosis). On awareness of osteogenesis imperfecta congenita and tarda (so-called "idiopathic osteopsatyrosis"). Mitteilungen aus den Grenzgebieten der Medizin und Chirurgie (Dispatches from the Frontier of Medicine and Surgery). 15. 161–207. de. 21 August 2021. 21 August 2021. https://web.archive.org/web/20210821080919/https://books.google.com/books?hl=en&lr=&id=gSQCAAAAYAAJ&oi=fnd&pg=PA161. live.
  150. Book: Double helix, double joy: David Danks, the father of clinical genetics in Australia. Rasmussen C, Danks A. 2010. Melbourne University Press. 978-0-522-85799-3. Carlton, Victoria. 116. English. 906592657. 28 August 2021. 28 August 2021. https://web.archive.org/web/20210828174208/https://books.google.com/books?id=L-BlM8uD6SYC&pg=PA116&lpg=PA116. live.
  151. Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, Mortier G, Mundlos S, Nishimura G, Rimoin DL, Robertson S, Savarirayan R, Sillence D, Spranger J, Unger S, Zabel B, Superti-Furga A . 6 . Nosology and classification of genetic skeletal disorders: 2010 revision . American Journal of Medical Genetics. Part A . 155A . 5 . 943–968 . May 2011 . 21438135 . 3166781 . 10.1002/ajmg.a.33909 .
  152. Web site: Osteogenesis Imperfecta (OI) in Dachshunds. live. 2021-08-28. UC Davis Veterinary Genetics Laboratory. UC Davis School of Veterinary Medicine. en. 28 August 2021. https://web.archive.org/web/20210828110155/https://vgl.ucdavis.edu/test/oi-dachshund.
  153. News: Osteogenesis Imperfecta (OI Dachsund). Center for Animal Genetics. Generatio GmbH. 2018-11-07. https://web.archive.org/web/20181108074324/https://www.centerforanimalgenetics.com/services/dog-genetic-testing/hereditary-disease-testing-for-dogs/osteogenesis-imperfecta/. 2018-11-08.
  154. Enderli TA, Burtch SR, Templet JN, Carriero A . Animal models of osteogenesis imperfecta: applications in clinical research . Orthopedic Research and Reviews . 8 . 41–55 . September 2016 . 30774469 . 6209373 . 10.2147/ORR.S85198 . free .
  155. Saban J, Zussman MA, Havey R, Patwardhan AG, Schneider GB, King D . Heterozygous oim mice exhibit a mild form of osteogenesis imperfecta . Bone . 19 . 6 . 575–579 . December 1996 . 8968022 . 10.1016/S8756-3282(96)00305-5 . 28 August 2021 . live . https://web.archive.org/web/20180630183333/https://linkinghub.elsevier.com/retrieve/pii/S8756328296003055 . 30 June 2018 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Osteogenesis imperfecta".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.